BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230919
DTEND;VALUE=DATE:20230922
DTSTAMP:20260515T051758
CREATED:20230726T074357Z
LAST-MODIFIED:20230726T074357Z
UID:37521-1695081600-1695340799@www.pharmajournalist.com
SUMMARY:7th IPF Summit
DESCRIPTION:FIbroGen’s recent Phase 3 trial failure for pamrevlumab exemplifies the critical time point the pulmonary fibrosis field is currently at as drug developers move through in-human to Phase 2 to Phase 3 trials to get the next disease-modifying drug to the patients in need. \nThe 7th IPF Summit (September 19-21 | Boston) returns at this crucial stage for the drug development and academic communities to come together to address R&D bottlenecks\, troubleshoot key discovery challenges\, and share exclusive data to accelerate the latest ideas and innovations in the IPF field and supercharge a new era of IPF therapeutics. \nIf you haven’t yet seen the line-up of 42+ expert speakers\, take a look at the full program in the event guide! \nAre you looking to address and solve challenges with IPF therapeutic development\, such as:   \n\nUnderstanding cell cross-talk in the lung pathobiology of IPF\, including epithelial and endothelial cells\nHarnessing precision medicine for IPF including patient selectivity\, combinational therapies\, and biomarkers\nWhether to incorporate imaging into your preclinical and clinical development and the potential of using imaging as an endpoint in IPF?\n\nThen this is the event for you! This is your unique opportunity to leverage knowledge from world-leading IPF industry experts and KOL academics on the latest developments to overcome\, discovery\, preclinical\, translational\, and clinical\, challenges of IPF therapeutic development for successful advancement of therapeutic candidates to in-human studies and beyond. \nJoin experts from the likes of Boehringer Ingelheim\, Genentech\, Pfizer\, AstraZeneca\, BMS\, Pliant\, Galecto\, Vicore\, Avalyn\, Pieris\, Moderna\, Takeda and more who have already saved their places at the meeting. \nSee pricing and registration options here!
URL:https://www.pharmajournalist.com/event/7th-ipf-summit/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230913
DTEND;VALUE=DATE:20230915
DTSTAMP:20260515T051758
CREATED:20230810T114925Z
LAST-MODIFIED:20230810T114925Z
UID:37605-1694563200-1694735999@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices USA
DESCRIPTION:Wearable Injectors and Connected Devices USA  \nConference: September\, 13 – 14 2023  \nBoston\, USA  \nWebsite: http://www.wearableinjectors-usa.com/PharmaJournalist-EL \nAdvancing digital health and on-body drug delivery devices for enhanced patient experience  \nFollowing the success of the Wearable Injectors and Connected Devices Europe conference\, SAE Media Group will be bringing the conference to Boston to cater to Big Pharma\, Biotech and Device Developers in the USA. \nAs the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows\, on-body injectors and connected devices hold great opportunity. The conference will delve into on-body device design and development\, latest advances in connectivity and digital integration of wearable devices\, and opportunities for enhancement of user-interface through human factors case studies. The conference will also address challenges in regulations surrounding wearable injectors and connected devices with case studies and an FDA keynote on cybersecurity. \nAs part of SAE Media Group’s leading Injectable series of conferences\, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in September 2023! \nKey Reasons to Attend: \n\nDiscover the latest advances in wearable injector design and development as well as emerging technologies for improved drug delivery\nUnderstand and gain insight into the regulations surrounding electronic devices and wearable injectors such as labelling requirements and clinical study expectations\nDelve into the digital integration of medical devices for improved user experience and strategies to ensure connected ecosystems are safe with an FDA Cybersecurity update\nBenchmark against connected injector case studies and gain insight into key considerations during development such as battery selection\nEngage in the latest strategies for implementing user centricity into device design to meet patient needs and increase adherence\n\nWHO SHOULD ATTEND? \nDevice Developers \nCombination Product Developers \nSmart Packaging Developers and Designers \nSmart Device Developers \nDrug- Delivery Developers \nConnected/Digital Health Developers
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-usa/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230915
DTSTAMP:20260515T051758
CREATED:20230720T121753Z
LAST-MODIFIED:20230720T121753Z
UID:37490-1694476800-1694735999@www.pharmajournalist.com
SUMMARY:3rd Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:Your one-stop shop to capturing industry’s most exciting developments to tackle rare & genetic kidney diseases. From evaluating real-world outcomes to uncovering underlying pathophysiology to interrogating translational models\, the 3rd Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to give industry the opportunity to unite towards a shared goal and share strategic insights to move from bench to bedside and bring efficacious therapies to patients faster. \nTo know more visit: https://ter.li/jy2ot0
URL:https://www.pharmajournalist.com/event/3rd-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230915
DTSTAMP:20260515T051758
CREATED:20230714T121304Z
LAST-MODIFIED:20230714T121304Z
UID:37455-1694476800-1694735999@www.pharmajournalist.com
SUMMARY:LNP Characterization & Analytical Development Summit
DESCRIPTION:Fingerprinting Your LNP Drug Product Quality\, Safety\, Efficacy & Regulatory Compliance \nWith the recent breakthroughs from Verve Therapeutics\, Vertex-Arbor Bio\, and Mana.bio propelling the field of LNP technology forward at lightning speed beyond mRNA vaccines\, the LNP Characterization & Analytical Development Summit is your must-attend meeting to deep dive into the latest technologies and approaches throughout product lifecycle and strengthen your lipid nanoparticle characterization\, bioanalytical and assay development competencies. \nWith unmissable case studies from the likes of Pfizer\, Moderna\, AstraZeneca\, Ultranegyx\, Merck and SINTEF\, this is the definitive forum to benchmark and learn with the LNP community who unite for the first time. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nAnalyze LNP structure and morphology to relay into functional data and analytical practices with Ultragenyx and Pfizer\nOptimize the characterization of payloads to foresee the outcome of the LNP complex with Hopewell Therapeutics\, Beam Therapeutics and Moderna\nDevelop assays which align with mechanisms of action and portray total functionality of the LNP with NIST\, Editas Medicine and AstraZeneca\n\nDon’t miss this opportunity to supercharge your analytics\, and together with 60+ characterization and analytical scientists\, get inspiration to derive best practice\, and support next generation of therapeutics to patients with safety and efficacy. \nTo know more visit: https://ter.li/z7dmih
URL:https://www.pharmajournalist.com/event/lnp-characterization-analytical-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230911
DTEND;VALUE=DATE:20230914
DTSTAMP:20260515T051758
CREATED:20230704T143300Z
LAST-MODIFIED:20230704T143518Z
UID:37419-1694390400-1694649599@www.pharmajournalist.com
SUMMARY:7th Complement-Based Drug Development Summit
DESCRIPTION:With the recent FDA approval of SYFOVRE and more decisions and approvals expected in 2023\, the Complement-Based Drug Development Summit is returning for its 7th year in a timely fashion. Be the first to view this year’s Event Guide below! \n7th Complement-Based Drug Development Summit\nSeptember 11-13\, 2023\nView Agenda \nReuniting experts across Nephrology\, Neurology\, Ophthalmology\, and Haematology\, join the leading companies showcasing the latest preclinical and clinical progress for complement-based therapeutics. \n\nWith 30+ expert speakers from: AGTC\, Alexion\, Alnylam\, Amgen\, Annexon\, Apellis – and that’s just the A’s!\nCovering more complement targets than ever before including C5aR2\, Factor Bb and Combination Therapy\, alongside an increased coverage of diseases\nFull of content for your whole team covering the most pressing challenges – from evaluating the value proposition of different fragments to target to designing clinical trials with high-risk patient populations\n\n \n​​​​View the full list of sessions and expert speakers here. \n​​​​​​This world-class speaker faculty will evaluate the entirety of the complement landscape\, from scientific understanding to strategic\, commercial intelligence. This means that no matter your role in the field\, you’ll leave with tangible insights to further develop your complement pipeline.
URL:https://www.pharmajournalist.com/event/7th-complement-based-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230909
DTSTAMP:20260515T051758
CREATED:20230606T104920Z
LAST-MODIFIED:20230606T104920Z
UID:37280-1693872000-1694217599@www.pharmajournalist.com
SUMMARY:13th World Clinical Biomarkers & CDx Boston 2023
DESCRIPTION:The hotly anticipated 13th World Clinical Biomarkers & CDx Summit returns as the only industry-led meeting uniting 600+ senior decision makers in the biomarker and CDx field to accelerate clinically validated and affordable co-development of drug-CDx by overcoming commercialization\, reimbursement and regulatory challenges in oncology and beyond to bring personalized medicine to patients faster. \nWhether you are working in Oncology\, NASH\, or Neuroscience\, join 600+ Directors\, Heads and VPs of Clinical Biomarkers\, Translational Medicine\, Precision Medicine & Companion Diagnostics together with drug and diagnostic developers\, regulatory experts\, payors and notified bodies for an exclusive opportunity of knowledge sharing and networking to propel your pipelines and make a marked difference for patient outcomes. \nTo know more visit: https://ter.li/849j6q
URL:https://www.pharmajournalist.com/event/13th-world-clinical-biomarkers-cdx-boston-2023/
LOCATION:Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230908
DTSTAMP:20260515T051758
CREATED:20230519T095236Z
LAST-MODIFIED:20230519T095236Z
UID:37210-1693872000-1694131199@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Immunogenicity Summit 2023
DESCRIPTION:The 4th Annual Gene Therapy Immunogenicity Summit is your opportunity to connect with likeminded peers from gene therapy drug developers\, along with leading academics\, regulators\, and key service providers\, all making strides with improving risk assessments\, monitoring\, and mitigating against AAV gene therapy immunogenicity. \nRegistering for 2023 will grant you access to keynote plenaries from leading gene therapy figures\, deep-dive discussions into pressing preclinical and clinical developments\, and highly appraised networking opportunities with 150+ of your peers\, all to leave you with the actionable tools\, insights\, and connections you need to enhance your immunogenicity-focused work. \nTo know more visit: https://ter.li/vk8xwq
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-immunogenicity-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230908
DTSTAMP:20260515T051758
CREATED:20230515T131825Z
LAST-MODIFIED:20230515T131825Z
UID:37179-1693872000-1694131199@www.pharmajournalist.com
SUMMARY:5th Exosomes Based Therapeutic Development Summit
DESCRIPTION:The 5th Exosome Based Therapeutic Development Summit returns with a refreshed program\, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications. \nThis year features a brand-new focus day on analytical development\, diving into characterization assays\, purification\, and potency assays to enable robust translation into the clinic. \nThis is the most comprehensive\, end-to-end meeting for industry personnel who are looking to fine-tune molecular components of exosomes\, achieve GMP manufacturing of EVs for clinical applications\, and successfully deliver payloads to the target tissue by evaluating route of administration to accelerate candidates towards commercialization. \nThe 2023 conference covers: \n\nEmerging standardized analytical strategies for optimized characterization\, purification\, and isolation to improve batch consistency and reproducibility towards successful scale-up\nKey pre-clinical and clinical updates across a range of therapeutic areas\nThe latest advancements of targeted delivery and therapeutic payloads\nThe challenges of large-scale manufacturing\nNavigating the complex regulatory landscape across the drug development timeline\n\nView the full agenda here: https://ter.li/q4fnpd
URL:https://www.pharmajournalist.com/event/5th-exosomes-based-therapeutic-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230901
DTSTAMP:20260515T051758
CREATED:20230516T103454Z
LAST-MODIFIED:20230516T103454Z
UID:37187-1693267200-1693526399@www.pharmajournalist.com
SUMMARY:3rd Inner Ear Disorders Therapeutics Summit
DESCRIPTION:The development of next-generation drug-based approaches to treat inner ear disorders is gaining momentum\, with multiple INDs approved in the last six months and big pharma making plays to acquire innovative biotechs working on hearing loss. \nHowever\, in a space that has also had to battle with multiple clinical failures\, there’s a genuine need for the industry to unite and overcome the specific obstacles that are currently acting as a barrier to late-stage clinical trials and through to approval. \nThat’s why the 3rd Inner Ear Disorders Therapeutics Summit is back this summer\, bringing together the community to collectively accelerate development of drug-based approaches\, sharing case studies and data-driven insights into optimizing preclinical programs and designing translational studies to ultimately validate clinically relevant targets. \nThis meeting will leverage the latest biotech and academic innovation alongside big pharma experience to address the technical and strategic challenges in delivering a safe and effective therapy to the inner ear. \nWhat to expect from the 2023 meeting: \n\nExplore how to improve clinical trial design to increase the number of clinical trials achieving regulatory approval\nDelve into the numerous delivery methods being employed in industry and explore how to optimize delivery to the inner ear\nEvaluate the current opportunities and limitations of using animal models to accurately predict preclinical efficacy and translational success\nLeverage valuable insights from VC investors to understand the key considerations made when investing in or forging partnerships with biotechs focussing on inner ear disorder therapeutics\nNavigate the complex landscape of improving the diagnostics of inner ear disorders by developing a robust diagnostic toolbox and strategizing how to supplement patient-reported outcome measures\n\nView the full agenda here: https://ter.li/a2ivra
URL:https://www.pharmajournalist.com/event/3rd-inner-ear-disorders-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230901
DTSTAMP:20260515T051758
CREATED:20230516T102107Z
LAST-MODIFIED:20230517T113503Z
UID:37184-1693267200-1693526399@www.pharmajournalist.com
SUMMARY:2nd Oligonucleotides CMC & Analytical Development Summit 2023
DESCRIPTION:Rapid development and rising demand of oligonucleotide drugs is fuelling revolutionary steps in biopharma investment and technology advancement for pipeline progression. The prospect of defining impurities and suitable CQAs for long-term scalable manufacturing looks to propel oligonucleotide development to patients at a much faster rate. \nThe 2nd Oligonucleotides CMC & Analytical Development Summit returns this August to Boston. 70+ industry leaders will unite at this unique forum dedicated to CMC and Analytical Experts. \nAcross 3 days\, senior leaders will leverage knowledge and share thought leadership focused on improving analytical characterization\, effectively preparing CMC data for IND filing and scaling up with long-term manufacturing in mind. \nBuilt with experts from AstraZeneca\, Alexion Pharmaceuticals\, Biogen \, revolutionize your drug development protocols by keeping your finger on the pulse at this hotly anticipated summit. \n\nExplore analytical control strategies for therapeutic oligonucleotides to ensure safety and quality with regulatory compliance\nOvercome the challenges of capacity when out-sourcing to propel and expedite oligonucleotide development\nGet interactive in roundtable discussions\, picking the brains of your peers and expert speakers on how biopharma is currently navigating the regulatory landscape\nFacilitate cost-efficient large-scale production of oligonucleotides now we are moving into larger patient populations and non-rare disease indications\nTurbocharge novel and complex oligonucleotide development in an in-depth workshop outlining CMC\, Analytical Characterization and Impurity Control of conjugates\n\nDownload your Full Event Guide Here for more details on what you can expect at the 2nd Oligonucleotides CMC & Analytical Development Summit. Including the expert speaker faculty\, a full in-depth agenda and the incredible networking and collaboration opportunities on offer this year.
URL:https://www.pharmajournalist.com/event/2nd-oligonucleotides-cmc-analytical-development-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230902
DTSTAMP:20260515T051758
CREATED:20230503T044916Z
LAST-MODIFIED:20230503T044916Z
UID:37116-1693267200-1693612799@www.pharmajournalist.com
SUMMARY:8th CAR-TCR Summit
DESCRIPTION:Last year was momentous for the cell therapy field: it was the year that CAR-T therapies became CURATIVE. \nThis decade of success has resulted in explosive investment into the development of CAR and TCR based approaches to ensure more patients around the world can benefit from these lifesaving therapies.   \nThe 8th CAR-TCR Summit is returning to Boston as the industry’s trusted\, definitive\, end-to-end forum for the global network of autologous and allogeneic cell therapy drug developers. Ensure your whole team stays ahead of the curve with unmatched industry insights shared across discovery through to commercialization.   \nAcross 3 conference days with 8 content tracks\, and an additional 6 deep-dive workshops\, bootcamp\, focus day\, diversity session\, C-level think tank and more\, 200+ CAR and TCR experts will lead you and over 1\,000 peers in discussions that will accelerate your pipeline\, bringing better drugs to patients faster. \nTo know more visit: https://ter.li/ztgick
URL:https://www.pharmajournalist.com/event/8th-car-tcr-summit/
LOCATION:Hynes Convention Center\, 900 Boylston St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230823
DTEND;VALUE=DATE:20230825
DTSTAMP:20260515T051758
CREATED:20230608T112726Z
LAST-MODIFIED:20230608T112726Z
UID:37312-1692748800-1692921599@www.pharmajournalist.com
SUMMARY:RNA Assay Development & Screening Summit
DESCRIPTION:Bringing together technical experts from biopharma and academia\, the brand-new RNA Assay Development & Screening Summit has been curated to support in-house assay development and screening strategies to find new RNA targets\, and ultimately determine biological effect in a manner that supports progression from early discovery to drug candidate. \nDeveloped in collaboration with experts in the field\, join 60+ key opinion leaders from the likes of Arrakis Therapeutics\, Expansion Therapeutics and NextRNA at the first technical RNA meeting of its kind! \nCome away with actionable insights after deep diving into the latest technical expertise and explore learnings from data-driven case studies. \nDon’t miss this unique opportunity expand and validate your assay and screening strategies and accelerate the path to the clinic! Learn more – https://ter.li/8fsu01
URL:https://www.pharmajournalist.com/event/rna-assay-development-screening-summit/
LOCATION:The Bostonian Boston\, 26 NORTH STREET\, BOSTON\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230822
DTEND;VALUE=DATE:20230825
DTSTAMP:20260515T051758
CREATED:20230406T130638Z
LAST-MODIFIED:20230406T130725Z
UID:37042-1692662400-1692921599@www.pharmajournalist.com
SUMMARY:2nd ADC Linker & Conjugation 2023
DESCRIPTION:Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field\, showing how they are being used as key levers for ADC drug developers to pull to create ADCs with a widened therapeutic index. \nThe inaugural ADC Linker & Conjugation Summit has been specifically designed to drive innovations in linker and conjugation chemistries that result in stable ADCs\, with low aggregation and controlled release\, which can be replicated at scale. \nSee the complete event guide here. \nHere’s a snapshot of our speaker faculty\, including expert industry leaders such as: \n\nSayumi Yamazoe\, Senior Principal Scientist\, Bristol Myers Squibb\nRomas Kudirka\, Director\, Chemistry & Bioconjugation\, Bolt Biotherapeutics\nDonglu Zhang\, Senior Fellow\, Genentech\nPaul Song\, Chief Scientific Officer\, Genequantum\nPatrick Higgs\, Principal Scientist\, Chemistry\, Iksuda\nNoah Bindman\, Principal Scientist\, Seagen\nMarc-André Kasper\, Director\, Chemistry & Early Discovery\, Tubulis\nPaul Sauter\, Director\, Chemistry\, VERAXA\n\n…and many more!\nFind the full list of speakers and session details here. \nBe part of the first industry-dedicated meeting for professionals just like you\, interested in learning about developments in the field of ADC linkers and conjugations\, and overcoming common challenges with stability.
URL:https://www.pharmajournalist.com/event/2nd-adc-linker-conjugation-2023/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230726
DTEND;VALUE=DATE:20230729
DTSTAMP:20260515T051758
CREATED:20230310T085409Z
LAST-MODIFIED:20230310T085611Z
UID:36783-1690329600-1690588799@www.pharmajournalist.com
SUMMARY:3rd mRNA-Based Therapeutics Summit
DESCRIPTION:The 3rd mRNA-Based Therapeutics Summit returns to Boston this July\, cementing its position as the world’s only end-to-end meeting focused on the next generation of mRNA-based therapeutics and vaccines. \nDownload the event program here. \nThis year’s meeting promises 75+ deep-dive case studies from a speaker faculty that is 85% new for this year’s agenda\, featuring presentations from the FDA\, Pfizer\, Moderna\, BioNTech\, Sanofi and many more. \n \nExpect 100+ world-class speakers from large pharma\, innovative biotechs\, and key opinion leaders of academia\, 5 dedicated tracks and 3 days of immersive content on discovery\, translation\, clinical development\, chemistry\, manufacturing and controls (CMC) and logistics to overcome industry hurdles of optimized dosing\, targeted delivery\, safety and scalability to achieve regulatory success in infectious and rare diseases\, cancer and beyond! \nRegister your team here to join 500+ mRNA experts in July.
URL:https://www.pharmajournalist.com/event/3rd-mrna-based-therapeutics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T051758
CREATED:20230608T113503Z
LAST-MODIFIED:20230608T113503Z
UID:37317-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:4th Gamma Delta T Therapies Summit
DESCRIPTION:Established industry leaders and emerging innovators such as Adicet Bio\, IN8Bio\, Sanofi\, Merck\, LAVA Therapeutics\, Takeda and Leucid Bio are driving the race to demonstrate the potential of Gamma Delta T Therapies as cytotoxic\, off-the-shelf solid tumor therapies\, spurred by early indications of clinical efficacy. \nThe 4th Gamma Delta T Therapies Summit returns to Boston this July as the ultimate Industry-focused forum to advance your Gamma Delta T research\, spanning dedicated 2 tracks of content to maximize your Clinical & Product Optimization and Research & Translational Development. Join 150+ expert industry peers for 2 full days of sessions and a pre-conference workshop and deep-dive day\, building on early clinical successes\, highlighting process and engineering innovations and leveraging early clinical insights to cast the spotlight onto Gamma Delta T Therapies in the clinic. \nTo know more visit: https://ter.li/69o2yc
URL:https://www.pharmajournalist.com/event/4th-gamma-delta-t-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T051758
CREATED:20230601T114828Z
LAST-MODIFIED:20230601T114828Z
UID:37256-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:Fusion Protein Engineering & Developability Summit
DESCRIPTION:Design & Engineer Functional & Manufacturable Novel Fusion Proteins \nPrepare to be captivated by the Fusion Protein Engineering & Developability Summit\, the ultimate event tailored to drug developers with groundbreaking fusion protein pipelines. This conference is an absolute game-changer that should be at the top of your priority list! \nAs the demand for practical and effective engineering techniques to expedite the development of viable drugs into clinical applications skyrockets\, this highly anticipated summit offers an unrivalled opportunity. Join forces with esteemed experts from industry giants like Roche\, Merck\, Bristol Myers Squibb\, Abbvie\, and an array of other distinguished names. Seize this unique occasion to connect with fellow drug developers\, exchange innovative ideas and strategies\, and gain invaluable insights into cutting-edge fusion applications. \nPrepare for a whirlwind of activity across the action-packed three-day agenda\, including: \n\nCutting-Edge Insights: Gain exclusive access to the latest breakthroughs in fusion protein engineering\, encompassing the most recent research and emerging trends in this dynamic field.\nPractical Learning: Immerse yourself in hands-on workshops led by industry experts\, designed to enhance your skills and knowledge in must-know areas.\nReal-World Case Studies: Immerse yourself in over 17+ data-driven case studies presented by renowned drug developers\, offering profound insights and best practices.\nEngaging Discussions: Engage in lively panel discussions and roundtable sessions\, fostering debates and knowledge exchange on hot topics such as novel linker selection and the identification of PK/PD rules.\nNetworking Opportunities: Forge valuable connections with 60+ protein engineers\, therapeutic developers\, and influential industry leaders during 7+ hours of dedicated networking\, including the renowned speed networking session.\n\nWith a stellar lineup of 25+ speakers\, 3 immersive hands-on workshops\, and 2 days packed with data-driven case studies\, this event is set to become the unequivocal highlight of the year and you cannot afford to miss it! \nTo know more visit: https://ter.li/uuyrdu
URL:https://www.pharmajournalist.com/event/fusion-protein-engineering-developability-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T051758
CREATED:20230516T104255Z
LAST-MODIFIED:20230516T104255Z
UID:37192-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:2nd Annual Targeted Radiopharmaceuticals Summit
DESCRIPTION:With the exciting news that Novartis has received US FDA approval for Pluvicto for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer\, the TRP space is continuing to go from strength to strength. \nThis is why the upcoming 2nd Annual Targeted Radiopharmaceuticals Summit US program is even more comprehensive than ever\, bringing you a tracked agenda covering the whole TRP landscape from discovery\, translation\, to clinical\, late stage progress and challenges – a unique opportunity for your entire team to learn and network. \nJoin us to: \n\nExplore the novel target selection to re-route targeted radiopharmaceuticals from a niche-label therapeutic\nNavigate the regulation and reimbursement challenges to improve the accessibility of targeted radiopharmaceuticals\nReview theragnostic in the clinic to exploit the two-birds-one-stone potential of TRPs\nDiscover the potential combination therapies with DDRi’s and IO to unlock synergy with other modalities\nHarness the platform technologies for optimized preclinical evaluation of drugs\n\nAll presented by top industry players such as Clarity Pharmaceuticals\, SOFIE Biosciences\, Lantheus\, Fusion Pharmaceuticals\, Rayze Bio\, Telix Pharmaceuticals\, OranoMed\, Actinium Pharmaceuticals\, and many more. \nDownload the brand-new event guide here to see a full overview 3-day content and speaker faculty: https://ter.li/8hn0z2
URL:https://www.pharmajournalist.com/event/2nd-annual-targeted-radiopharmaceuticals-summit/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T051758
CREATED:20230405T225751Z
LAST-MODIFIED:20230405T225751Z
UID:37019-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:ADC Toxicity Summit
DESCRIPTION:There is a vast number of ADCs that never make it to the clinic let alone to market\, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity\, their translatability into the clinic\, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures. \nThe inaugural ADC Toxicity Summit is coming to Boston\, MA this July 25-27 as the first and only meeting dedicated to enabling drug developers to analyze mechanisms of action\, discuss shared challenges associated with translating in vivo toxicity data to the clinic\, and optimizing dosing to minimize the toxicity of your drug and improve tolerability to bring more ADCs with a wider therapeutic index to market. \nTake a look at our 3-day event guide for your in-depth roadmap to the ADC Toxicity Summit. \nUniting all key stakeholders invested in this conversation ranging from toxicologist and pathologists\, through to nonclinical\, translational\, and clinical experts\, this is your exclusive opportunity to harness never before gained insights to deliver a safer and more tolerable generation of ADCs to patients. \n3 reasons why you can’t miss out on joining include: \n\nSelect optimal preclinical models for determining ADC toxicity profiles to enable improved translatability and ultimately improve clinical trial outcomes with Seagen and AbbVie\nHear how companies with commercially approved ADCs mitigated toxicities in the clinic\, and optimized their dosage allowing expansion of their therapeutic windows with ImmunoGen and the Dana Farber Cancer Institute\nUncover ideal linker stability and drug-antibody ratios to design an ADC with a lower toxicity profile with Bristol Myers Squibb\, Iksuda and Merck & Co\n\nHarnessing case-study led presentations and interactive discussions to enable you to select optimal models for your GLP toxicity studies\, mitigate ADC related toxicities in the clinic and optimize linker-design for more controlled payload release\, this is your exclusive opportunity to harness new insights to minimize the toxicity of your drug.
URL:https://www.pharmajournalist.com/event/adc-toxicity-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230718
DTEND;VALUE=DATE:20230721
DTSTAMP:20260515T051758
CREATED:20230414T110135Z
LAST-MODIFIED:20230414T110135Z
UID:37065-1689638400-1689897599@www.pharmajournalist.com
SUMMARY:3rd Tumor Myeloid-Directed Therapies Summit
DESCRIPTION:The 3rd Annual Tumor Myeloid-Directed Therapies Summit returns with over 75% new speakers to share insights across a range of myeloid targets\, including CD40\, CD39\, LILRB2\, CLEC-1 as well as CAR-M therapies. The one-stop shop continues to be your go-to forum to accelerate myeloid therapy progression by determining optimal combination strategy\, optimize translational studies\, discover novel targets\, and guarantee patient safety. Connect with this up-and-coming community to reinvent targeting and harness the untapped potential of the myeloid. \nCollaborate and learn from myeloid experts across industry and academia over 3 in-depth days of content\, as they address the key bottlenecks limiting the efficacy and safety of these exciting treatments\, including in vivo models\, biomarkers of response\, combination rationale\, and myeloid biology to accelerate myeloid directed therapies. \nTo know more visit: https://ter.li/tm1bzy
URL:https://www.pharmajournalist.com/event/3rd-tumor-myeloid-directed-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230712
DTEND;VALUE=DATE:20230714
DTSTAMP:20260515T051758
CREATED:20230404T110544Z
LAST-MODIFIED:20230404T110544Z
UID:37012-1689120000-1689292799@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit US 2023
DESCRIPTION:The Advanced Wound Care Summit is wound care’s only industry-led forum \nIt’s a chance for senior executives to address shared challenges around innovative product development\, build meaningful partnerships\, and sharpen their R&D and commercial strategies. \nWhether an established wound care company\, an emerging startup\, an SME\, a regulator\, a payer\, or key opinion leader\, this event serves your strategic and commercial goals. \nTo take this chance to uncover how leading figures are leveraging novel clinical trial designs\, addressing reimbursement challenges surrounding skin substitute products\, progressing next generation diagnostic innovations\, and much more. \nTo know more visit: https://hubs.ly/Q01J-t480
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit-us-2023/
LOCATION:Boston\, Massachusetts
ORGANIZER;CN="Kisaco Research":MAILTO:Jodie.purser@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230711
DTEND;VALUE=DATE:20230714
DTSTAMP:20260515T051758
CREATED:20230405T231354Z
LAST-MODIFIED:20230405T231354Z
UID:37027-1689033600-1689292799@www.pharmajournalist.com
SUMMARY:2nd Annual Optimizing AAV Safety Summit 2023
DESCRIPTION:With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice\, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be. \nIn this context\, the 2nd Annual Optimizing AAV Safety Summit is returning in 2023\, bringing together genetic therapy leaders across non-clinical development\, clinical development\, toxicology\, biodistribution\, and immunology who are all working to optimize the safety of their AAV-based drug products in their day-to-day. \nBy addressing key topics including how to extract the most relevant data from preclinical studies to better inform how humans will respond to an AAV-based therapy in the clinic\, analyzing potential integration risks of AAV serotypes\, and investigating regulatory approaches to safety packages for submission\, this meeting will inform how to streamline AAV safety processes to de-risk delays and shorten timelines to approval. \nJoin us in Boston to be part of the solution to bringing safer\, effective genetic therapies to patients and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development. \nTo know more visit: https://ter.li/6gzgy4
URL:https://www.pharmajournalist.com/event/2nd-annual-optimizing-aav-safety-summit-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230711
DTEND;VALUE=DATE:20230714
DTSTAMP:20260515T051758
CREATED:20230302T092937Z
LAST-MODIFIED:20230302T092937Z
UID:36706-1689033600-1689292799@www.pharmajournalist.com
SUMMARY:2nd Digital Biomarkers & Clinical Measures in Neurology Summit
DESCRIPTION:CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders through more objective\, frequent\, sensitive\, and less invasive measures of movement\, speech\, and cognition. \nReturning to Boston\, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit is the only industry-specific meeting dedicated to developing translatable\, scalable\, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials. \nThis is your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development. \nUniting Digital Health Biopharma with CNS Clinical Drug Developers to: \n\nAddress the Standardization & Regulatory Acceptance of Digital Tools & Data Analysis as Endpoints in Complex Neurological Indications\nDiscover Novel Innovations for Objective\, Sensitive\, & Non-Invasive Neurological Measures\nEnsure Confidence & Scalability with Emerging Digital Technologies\n\nTo know more visit: https://ter.li/nx0m2f
URL:https://www.pharmajournalist.com/event/2nd-digital-biomarkers-clinical-measures-in-neurology-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230628
DTEND;VALUE=DATE:20230701
DTSTAMP:20260515T051758
CREATED:20230413T095125Z
LAST-MODIFIED:20230413T095125Z
UID:37050-1687910400-1688169599@www.pharmajournalist.com
SUMMARY:8th Microbiome Movement Drug Development Summit
DESCRIPTION:The 8th Microbiome Movement Drug Development Summit returns in 2023 as North America’s definitive microbiome drug development event – and it’s back bigger and better than ever! \nThe microbiome-based therapeutic market is rapidly evolving\, and it’s more important than ever to showcase the efficacy of microbial-based approaches beyond C. difficile. Discover how drug developers are advancing their understanding of the role of the microbiome in disease and harnessing functionally relevant microbes for live biotherapeutic approaches. \nJoin us\, as we provide in-depth insights into the interactions between the microbiome and metabolic pathways\, host-microbe relationships in novel preclinical models\, and the application of microbial-based biomarkers in clinical endpoints and diagnostic settings. Our sessions also cover the mechanistic rationale behind combination therapies\, new smart clinical trial data\, and GMP compliant manufacturing for stable products. \nWith more speakers\, content\, and networking than ever before\, this is set to be the best version of the event yet and you cannot afford to miss it! \nTo know more visit: https://microbiome-summit.com/
URL:https://www.pharmajournalist.com/event/8th-microbiome-movement-drug-development-summit/
LOCATION:Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230627
DTEND;VALUE=DATE:20230630
DTSTAMP:20260515T051758
CREATED:20230207T095639Z
LAST-MODIFIED:20230207T095639Z
UID:36549-1687824000-1688083199@www.pharmajournalist.com
SUMMARY:3rd Annual Next Generation Gene Therapy Vectors Summit
DESCRIPTION:As the biggest industry-led meeting on novel vector development\, the 3rd Annual Next Generation Gene Therapy Vectors Summit (June 27-29\, 2023 | Boston\, MA) will bring together 100+ key opinion leaders to help solve the safety\, efficiency\, and scalability challenges of the next generation of vectors. \nIndustry heavyweights such as Novartis\, Spark Therapeutics\, Capsida Biotherapeutics\, and Dyno Therapeutics will deliver data-led seminars\, workshops\, and panels to aid in the progression of promising vector designs from discovery to clinical trials. \nDownload the brochure to see the full agenda – https://ter.li/b6qdwn \nUniting industry pioneers such as Dave Chu (Capsida Biotherapeutics)\, Sean Armour (Spark Therapeutics)\, Eric Kelsic (Dyno Therapeutics)\, Jing Liao (Alexion Pharmaceuticals)\, and others – this summit will be your ultimate roadmap to the future of the industry as it upgrades to the next generation of vectors. \nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/qlplw9
URL:https://www.pharmajournalist.com/event/3rd-annual-next-generation-gene-therapy-vectors-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230621
DTEND;VALUE=DATE:20230623
DTSTAMP:20260515T051758
CREATED:20230309T105108Z
LAST-MODIFIED:20230309T105108Z
UID:36775-1687305600-1687478399@www.pharmajournalist.com
SUMMARY:Antimicrobial Resistance Connect Europe
DESCRIPTION:This event will take place in London on 21-22 June 2023 in London\, focusing on the three biggest priorities enabling growth in the AMR field – Innovation\, Investment & Policy – AMR Connect enables you to foster connections with key stakeholders in anti-microbial research and build actionable next steps to combat the silent pandemic. \n \nAMR Connect provides your team with the opportunity to create actionable steps within an interdisciplinary environment\, creating a unified approach across sectors. The demand to innovate and advance the way we tackle resistance is paramount and commanding the attention of nations globally – book your place now and join us in tackling the silent pandemic. \nBenefits of attending \n\nWith AMR considered one of the top 10 public health threats globally\, uncover how different regions are developing effective policy guidelines and incentive schemes that work for their region – with sessions from ReAct Latin America\, Asia-Europe Foundation\, WHO and many more.\nApply for the Innovation Showcase\, showcasing your state-of-the-art research in drug development\, diagnostics or one health in front of our room of investors\, pharma and solution providers.\nStreamline your route from discovery to market through case studies from Arrepath and Madam Therapeutics on the utilisation of AI/ML to reduce drug development timescales.\nMeet your next partner and foster connections across stakeholders through future-focussed roundtables on the biggest challenges impacting the field – including regulation\, policy and the future of anti-infectives.\n\nTake advantage of the early bird discount ending on 24 March. Book now to SAVE up to £700.
URL:https://www.pharmajournalist.com/event/antimicrobial-resistance-connect-europe/
LOCATION:LONDON\,UK
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260515T051758
CREATED:20230330T101610Z
LAST-MODIFIED:20230330T102722Z
UID:36955-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit
DESCRIPTION:Exciting results are expected this year\, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73\, CD39 and A2AR! \nTo ensure the community can capitalize on this\, the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit will be returning this June (20 – 22) in Boston\, MA – dedicated to bringing together 80+ industry experts to tackle the biggest problems the field continues to face in discovering translating and clinically developing CD73\, CD39\, A2A and A2B focused therapeutics. \nJoin this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage\, utilize novel technologies and approaches through translation to clinical development to improve patient selection\, and discover new ways of finding mono and combo therapy approaches to increase potency and safety. \nTop Speakers includes: \n\nAlex Gaither\, Vice president from Exscientia AI – evaluating ways to improve preclinical engineering practices for adenosine mono & combo therapeutics candidates\nChangyun Hu\, CSO from Adept Therapeutics – deep diving into preclinical and clinical Adenosine receptor targeting and more\nJoanne Lager\, Chief Medical Officer from iTeos Therapeutics – looking beyond T Cell and assessing potential outcomes for the Adenosine field in the event of an approval or major failure\n\n& 15+ more expert speakers! \nDownload your copy of the newly released agenda to find everything that will help you translate and clinically develop your adenosine therapeutic: https://ter.li/hende5 \nInterested in speaking? Contact info@hansonwade.com \nInterested in sponsoring? Contact sponsor@hansonwade.com
URL:https://www.pharmajournalist.com/event/2nd-annual-adenosine-pathway-targeted-cancer-immunotherapy-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260515T051758
CREATED:20230314T122048Z
LAST-MODIFIED:20230314T122048Z
UID:36825-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:Next Gen Inhalation Delivery Summit
DESCRIPTION:With exciting developments in pioneering inhaled drug products from Moderna\, Vertex\, ReCode Therapeutics\, and Pieris Pharmaceuticals\, now is the time to go full speed ahead on your efforts into inhaled formulation and delivery optimization. Despite the inhalation drug delivery market being expected to reach $18.6 billion by 2029\, achieving cell-specific delivery\, and optimized stability remain vital challenges. \nThis June\, the hotly anticipated Next Gen Inhalation Delivery Summit will debut\, where we will unite 80+ senior leaders at this definitive meeting dedicated to the inhalation community. Whether your work in COPD\, asthma\, IPF\, lung cancer or infectious disease\, this comprehensive forum offers the solution to capitalize on the common goal of targeted lung delivery. \nBe part of the conversation in Boston this June\, where we unpick: \n\nOvercoming pulmonary biological barriers to minimize dosage and maximize therapeutic benefit\nAdvancing your inhalation formulation techniques for improved stability and longer shelf-lives\nEnsuring device-formulation compatibility with patient compliance and patient convenience\n\nWith key speakers from the likes of Janssen\, Avalyn Pharma\, and FDA\, exciting content\, and networking opportunities\, you cannot afford to miss out! \nTo know more visit: https://ter.li/hlg9tw
URL:https://www.pharmajournalist.com/event/next-gen-inhalation-delivery-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T051758
CREATED:20230503T050638Z
LAST-MODIFIED:20230503T050638Z
UID:37123-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:3rd ILD Summit
DESCRIPTION:Returning for the 3rd year\, the ILD Summit will lean into the industry’s key challenges\, explore pipeline opportunity development\, and look towards the future for ILD therapeutic development from idiopathic pulmonary fibrosis pipelines. From illuminating predictors of progression to define and identify the progressive fibrosis phenotypes for patient stratification to evolving clinical trial design with novel secondary and exploratory endpoints beyond FVC. This is a fantastic point in 2023 for the lung fibrosis community to come together to meet at the intersection of pulmonology and rheumatology to advance therapeutic development for ILDs. \nTo know more visit: https://ter.li/wc2uto
URL:https://www.pharmajournalist.com/event/3rd-ild-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T051758
CREATED:20230320T154738Z
LAST-MODIFIED:20230320T154738Z
UID:36873-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:Temperature Control and Logistics Summit
DESCRIPTION:Advance your end-to-end logistics strategy to deliver vital therapeutics at the RIGHT TIME\, RIGHT PLACE and the RIGHT TEMPERATURE \nJoin us in Frankfurt in June 2023 in a brand-new venue at the heart of Europe\, as once again\, we return live and in-person for 3 days of interactive sessions\, collaborative roundtables as well as formal and informal networking to maximise the value of shared insights and open discussions. \nWe meet at a time of great challenge and opportunity. How can we mitigate risk and ensure quality whilst adopting the new technologies essential to future success? In what ways can we bolster the resilience of our supply chains without compromising operational agility? How can we build a supply chain and logistics network that is both effective and environmentally sustainability? \nOnly in partnering across the supply chain can we confront these challenges; and as a community that thrives on innovation and collaboration\, we’ve built a programme centred on the fundamental challenges of our time\, including how we: \n>> Drive Digital Transformation Throughout The Supply Chain To Achieve Full End-To-End Visibility\n>>Enhance Supply Chain & Logistics Network Design To Bolster Resilience\, Security & Efficiency\n>> Partner Across The Network To Meet The Demands of An Increasingly Complex Operating Environment\n>> Leverage New Packaging Innovation To Ensure Quality & Demonstrate Regulatory Compliance\n>> Build An Environmentally Sustainability Temperature Controlled Supply Chain \nTCL 2023 will provide a deep-dive into what these industry developments mean for Pharmaceutical Logistics\, Quality Assurance & Supply Chain practitioners and focus on delivering a mix of interactive sessions\, which will enable delegates to leverage the collective knowledge of their peers and brainstorm solutions to the challenges\, which the industry is facing. \nTCL doesn’t just stand for Temperature Control and Logistics\, now it also stands for Transformation\, Collaboration and Learning! >> Download the full agenda to view full speaker line-up\, discussion details\, sponsorship opportunities\, and more!
URL:https://www.pharmajournalist.com/event/temperature-control-and-logistics-summit/
LOCATION:Sheraton Frankfurt Airport Hotel & Conference Center\, Hugo-Eckener-Ring 15/Terminal 1\, Frankfurt am Main\, 60549\, Germany
ORGANIZER;CN="IQPC Limited":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T051758
CREATED:20230228T084503Z
LAST-MODIFIED:20230228T084623Z
UID:36697-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Patient Engagement
DESCRIPTION:As the global healthcare system accelerates its acceptance of gene therapies as one-time\, potentially curative\, treatment options for rare diseases\, the role of patient engagement in informing drug development strategy is evolving. \nAt this interface lies the 3rd Gene Therapy Patient Engagement Summit\, uniting patient advocacy and engagement experts from leading gene therapy and gene editing drug developers\, along with patient groups and patients themselves. Talks\, workshops\, and group discussions will shed a light on how to better integrate the patient voice into gene therapy programs at crucial stages of the drug development process. \nJoin us in Boston this summer to gain the actionable insights\, tools\, and strategies you need to better implement patient input into patient-centric gene therapy programs. \nTo know more visit: https://ter.li/rbofji
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-patient-engagement/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR